Faktore patologikoak @page { } table { border-collapse:collapse; border-spacing:0; empty-cells:show } td, th { vertical-align:top; font-size:12pt;} h1, h2, h3, h4, h5, h6 { clear:both } ol, ul { margin:0; padding:0;} li { list-style: none; margin:0; padding:0;} <!-- "li span.odfLiEnd" - IE 7 issue--> li span. { clear: both; line-height:0; width:0; height:0; margin:0; padding:0; } span.footnodeNumber { padding-right:1em; } span.annotation_style_by_filter { font-size:95%; font-family:Arial; background-color:#fff000; margin:0; border:0; padding:0; } * { margin:0;} .gr1 { color:#eaeaea; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.125cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.125cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; min-height:1.27cm;} .gr2 { color:#eaeaea; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.125cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.125cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; min-height:1.27cm;} .gr3 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr4 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr5 { font-size:24pt; writing-mode:lr-tb; } .gr6 { color:#eaeaea; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.13cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; } .gr7 { color:#eaeaea; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.13cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; } .gr8 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .P1 { font-size:14pt; } .P10 { margin-left:0cm; margin-right:0cm; text-indent:0cm; } .P11 { text-align:center ! important; writing-mode:lr-tb; } .P12 { margin-left:0cm; margin-right:0cm; margin-top:0.74cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P13 { margin-left:0cm; margin-right:0cm; margin-top:0.529cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P14 { margin-left:0cm; margin-right:0cm; margin-top:0.476cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P15 { margin-left:0cm; margin-right:0cm; margin-top:0.846cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P16 { margin-left:0cm; margin-right:0cm; margin-top:0.846cm; margin-bottom:0cm; line-height:90%; text-align:justify ! important; text-indent:0cm; } .P17 { margin-left:0cm; margin-right:0cm; margin-top:0.705cm; margin-bottom:0cm; line-height:90%; text-align:justify ! important; text-indent:0cm; } .P18 { margin-left:0cm; margin-right:0cm; margin-top:0.423cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P19 { margin-left:0cm; margin-right:0cm; margin-top:0.317cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P2 { text-align:right ! important; font-size:14pt; } .P20 { margin-left:1.27cm; margin-right:0cm; margin-top:0cm; margin-bottom:0cm; line-height:100%; text-align:left ! important; text-indent:0cm; writing-mode:lr-tb; } .P21 { margin-left:0cm; margin-right:0cm; margin-top:0.74cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P22 { margin-left:0cm; margin-right:0cm; margin-top:0.476cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P23 { margin-left:0cm; margin-right:0cm; margin-top:0.635cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P24 { margin-left:2.063cm; margin-right:0cm; margin-top:0.635cm; margin-bottom:0cm; line-height:90%; text-indent:-0.793cm; } .P25 { margin-left:0cm; margin-right:0cm; margin-top:0.846cm; margin-bottom:0cm; text-indent:0cm; } .P26 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; text-indent:0cm; } .P27 { margin-left:0cm; margin-right:0cm; margin-top:0.529cm; margin-bottom:0cm; text-indent:0cm; } .P28 { margin-left:0cm; margin-right:0cm; margin-top:1.27cm; margin-bottom:0cm; text-indent:0cm; } .P3 { writing-mode:lr-tb; } .P4 { margin-left:0cm; margin-right:0cm; line-height:100%; text-indent:0cm; } .P5 { margin-left:0cm; margin-right:0cm; line-height:100%; text-indent:0cm; writing-mode:lr-tb; } .P6 { margin-left:0cm; margin-right:0cm; line-height:100%; text-align:center ! important; text-indent:0cm; } .P7 { margin-left:0cm; margin-right:0cm; line-height:100%; text-align:center ! important; text-indent:0cm; writing-mode:lr-tb; } .P8 { margin-left:0cm; margin-right:0cm; line-height:100%; text-align:right ! important; text-indent:0cm; } .P9 { margin-left:0cm; margin-right:0cm; line-height:100%; text-align:right ! important; text-indent:0cm; writing-mode:lr-tb; } .T1 { color:#eaeaea; font-size:12pt; text-shadow:1pt 1pt; } .T10 { font-size:20pt; font-style:italic; } .T11 { font-size:20pt; } .T12 { font-size:24pt; } .T13 { font-size:24pt; } .T14 { font-size:24pt; } .T15 { font-size:24pt; } .T16 { font-size:40pt; } .T17 { color:#ffff99; font-size:32pt; } .T18 { color:#ffff99; font-size:32pt; font-weight:bold; } .T19 { font-size:18pt; } .T2 { color:#ffffcc; font-size:57pt; } .T20 { color:#eec85e; text-decoration:underline; } .T21 { color:#eaeaea; } .T22 { color:#eaeaea; font-size:18pt; font-style:normal; text-shadow:none; text-decoration:none ! important; font-weight:normal; } .T23 { color:#eaeaea; font-size:18pt; font-style:italic; text-shadow:none; text-decoration:none ! important; font-weight:normal; } .T24 { color:#eaeaea; font-size:18pt; font-style:normal; text-shadow:none; text-decoration:underline; font-weight:normal; } .T25 { color:#eec85e; } .T26 { font-size:24pt; } .T27 { font-size:24pt; } .T28 { font-size:18pt; } .T29 { font-size:18pt; } .T3 { color:#ffffcc; font-size:48pt; } .T30 { font-size:24pt; } .T31 { font-size:24pt; } .T32 { color:#ffffff; font-size:24pt; } .T33 { color:#ffffff; font-size:24pt; } .T34 { color:#ffffff; font-size:24pt; } .T35 { color:#ffffff; font-size:24pt; } .T36 { color:#ffffff; font-size:24pt; } .T37 { font-size:32pt; font-weight:bold; } .T38 { font-size:24pt; text-decoration:underline; } .T39 { font-size:24pt; } .T4 { font-size:36pt; } .T40 { font-size:24pt; font-style:italic; } .T41 { font-size:36pt; font-weight:bold; } .T42 { font-size:36pt; } .T43 { font-size:28pt; font-weight:bold; } .T5 { color:#ffff00; font-size:28pt; font-weight:bold; } .T6 { font-size:20pt; } .T7 { font-size:20pt; } .T8 { font-size:18pt; font-style:italic; } .T9 { font-size:20pt; } <!-- ODF styles with no properties representable as CSS --> .dp1 .dp2 .dp3 .dp4 .T44 { } Faktore patologikoak Giltzurrunetako gutxiegitasuna Aldaketa farmakozinetikoakXurgapena –Urdailaren pHaren eraldaketa Banaketa  farmako azidoen plasma proteinekiko finkapena (fenitoina, penizilina, salizilatoak…) –↑ [1-glikoproteina azidoa] → ↑ farmako basikoen plasma proteinekiko finkapena Metabolismoa  azetilazioa (isoniazida, prokainamida…)  esterasa plasmatikoen eragina (prokaina) Iraizketa –Farmako/metabolitoen metaketa → Toxikotasuna ↑ Opiazeoek eta hipnotikoek eragindako eragin kaltegarriak ↑ Digitalikoek sortutako toxikapenak ↑ NSZean akziogunetzat duten farmakoen eragina ↑ Zenbait farmakoen eragin kolinergikoak ↑ Antikoagulatzaileen eragina ↑ Antihipertentsiboek eragindako jarreragatiko hipotentsioa  Lakioaren diuretikoen eraginkortasuna Aldaketa farmakodinamikoak Giltzurrunetako funtzio-maila zehaztea –Kreatininaren aklaramendua Tratamendu farmakologikoaren beharra aztertzea Medikamentuaren hautaketa Dosiaren egokipena –Cl < 50 ml/min →  dosi edo ↑ tartea Erantzun farmakologikoaren monitorizazioa Irizpide orokorrak preskripziorako Farmakoek eragindako nefrotoxikotasunaFarmako gehienak giltzurrunen bidez kanporatzen dira Giltzurrunak farmakoak kontzentratzen dituenez mailak odolean baino altuagoak dira GGA-ren %5-20 farmakoek eragindakoak dira –Eragin toxiko zuzena –Zeharkako asaldura prezipitazioagatik (farmako, kaltzio edo azido uriko) Gutxiegitasun hepatikoa Aldaketa farmakozinetikoakXurgapena –↑ Biodisponibilitatea ( 1. pausua) Banaketa  Plasma proteinekiko finkapena (hipoalbuminemia) Metabolismoa – I motako prozesuetan (oxidazioa, erreduzioa, hidroxilazioa) II motakoetan (konjugazioa) baino eraldaketa sakonagoa Iraizketa –Zirrosia →  Cl + ↑ ura eta Na-ren erretentzioa Gatzapenaren aldaketak Entzefalopatia hepatikoa Hepatotoxikotasuna ↑ NSZeko farmako depresoreen eragina ↑ Antikoagulatzaileen eragina Aldaketa farmakodinamikoak Arrisku/onura aztertzea Hepatotoxikoak ez diren farmakoak aukeratzea Gibelean eraldatuak izan gabe giltzurrun iraizketaz kanporatzen diren farmakoak aukeratzea SNZ-ean eragina duten farmakoak ekiditzea Dosi txikiak erabili tratamenduaren hasieran Eragin kaltegarrien agerpena behatzea Irizpide orokorrak preskripziorako FARMAKOEK ERAGINDAKO HEPATOPATIAFarmako gehienen metabolismorako gunea Hepatopatiak %10, gibeleko bat-bateko porrota %15-30, hepatitis kroniko ez-birikoa %20-50 500-1000 medikamentu hepatopatiak eragin ditzakete Hepatotoxina zuzenak  karbonoaren tetrakloruroa, fosforoa... Hepatotoxina zeharkakoak  tetraziklinak, metotrexato, parazetamola... Profilaxia Farmakoak bakarrik erabili ezinbestekoa denenean Erabilpenaren aurreko esperientzia duten farmakoak erabili Dosi egokiak Elkarketak ekiditu Hepatotoxikotasunerako arrisku-faktoreak kontutan hartu Farmakoek eragindako hepatotoxikotasuna ahalik eta azkarren diagnostikatu Hepatotoxikotasunaren aurrekinak dituzten pazienteek era egokian identifikatu Eragin desiragaitz hepatotoxikoak aditzera eman Farmakoek eragindako hepatotoxikotasuna bultzatzen duten faktoreak Hepatotoxikotasunaren prebalentzia >%1  Takrina, isoniazida, karbamazepina, amiodarona, balproikoa, nitrofurantoina... %0,1-1  Sulfamidak, klorpromazina, fenitoina... %0,1-0,01  Salizilatoak, eritromizina, ketokonazol... <%0,01  Zimetidina, halotano, heparina...
